13 results about "Tube formation" patented technology

The invention provides a nucleic acid molecule, a mesenchymal stromal cell for promoting angiogenesis and application thereof, and relates to the technical field of biomedicine, the nucleic acid molecule encodes an HGF protein, or encodes a VEGF165 protein and an HGF protein; the first signal peptide is used as a signal peptide of VEGF165 protein, and the second signal peptide is used as a signal peptide of HGF protein. Through a gene modification strategy, the MSC cell containing the nucleic acid molecule stably and efficiently expresses VEGF165 and / or HGF, and the expression quantity of the VEGF165 and / or HGF is obviously higher than that of the MSC without the nucleic acid molecule. The capability of promoting endothelial cell migration is realized; meanwhile, the cells can also remarkably promote proliferation and tube formation of HUVEC cells, and the strong angiogenesis promoting effect of the cells is further proved. The technical problem that in the prior art, nucleic acid molecules for expressing VEGF165 or / HGF cannot be stably and efficiently expressed is solved.

The invention belongs to the technical field of protein polypeptides, and particularly discloses a CD93 affinity peptide and application thereof in preparation of antitumor drugs or detection reagents. The polypeptide with a CD93 protein affinity effect is obtained through repeated screening and optimization, and an affinity blocking activity experiment proves that the CD93 affinity peptide can affine an extracellular IgV-like structural domain of the CD93 protein and block the interaction of CD93 / IGFBP7 protein. An HUVECs cell in-vitro migration experiment and a tube formation experiment verify that the CD93 affinity peptide can inhibit migration of HUVECs cells and tube formation, promote normalization of tumor vascular functions and further inhibit growth of tumors, and has no obvious toxic or side effect. The CD93 affinity peptide provided by the invention can be used for preparing anti-tumor drugs (including anti-tumor immunotherapy drugs) or detection reagents taking CD93 as a target spot, has a better medical application prospect, and provides a new choice for tumor immunotherapy.

The invention discloses injectable hydrogel for treating periodontitis as well as a preparation method and application of the injectable hydrogel. The injectable hydrogel is prepared from the following raw materials: chitosan and derivatives thereof, oxidative modified natural polysaccharide and modified hydroxyapatite, the modified hydroxyapatite comprises hydroxyapatite, and the surface of the hydroxyapatite is modified with a metal polyphenol network. The modified hydroxyapatite has multiple functions of oxidation resistance, immunoregulation, osteogenesis promotion, migration promotion, tube formation promotion, antibiosis and the like, and can be combined with the injectable hydrogel with biological adhesion and self-healing performance to realize better in-vivo tissue healing. The injectable hydrogel of the composite functional hydroxyapatite nanoparticles synthesized by the invention has biocompatibility, oxidation resistance, immunoregulation performance, osteogenesis promotion performance and antibacterial performance, and can realize better alveolar bone regeneration and repair in a rat periodontitis model, and the effect of the injectable hydrogel is superior to that of clinically common minocycline.

The utility model discloses a confocal perforated plate for tube formation experiment, which comprises a base plate structure, accommodating hole structures and bulge structures, the accommodating hole structures are equidistantly arranged on the upper surface of the base plate structure, and the bulge structures are arranged at the bottoms of the inner walls of the accommodating hole structures. According to the confocal perforated plate for the tube forming experiment, self-leveling of matrigel is achieved through combination of micron-sized annular protrusion arrays designed at the bottoms of the holes and super-hydrophilic surface modification, the standard deviation of the thickness of a gel layer is controlled within + / -3 microns, and the height difference of the liquid level is reduced to lt through side wall gradient hydrophobic treatment (top hydrophobic / bottom hydrophilic); 0.1 mm, and halo artifacts in confocal imaging are eliminated.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of H2AC19 in lung adenocarcinoma detection and treatment. Specifically, the research proves that H2AC19 is abnormally highly expressed in a lung adenocarcinoma patient, and the highly expressed H2AC19 is significantly related to the poor prognosis of the lung adenocarcinoma patient. In-vitro and in-vivo angiogenesis and tumor growth can be inhibited by knocking out H2AC19, and the proliferation, migration and tube formation capabilities in a co-culture model of lung adenocarcinoma cells and human umbilical vein endothelial cells are reduced. Meanwhile, the invention further discloses a new mechanism of H2AC19 for regulating and controlling angiogenesis through a p300 / EGR1 / MMP-1 pathway. The invention not only provides a more excellent method for diagnosis and prognosis evaluation analysis of lung adenocarcinoma, but also constructs an experimental basis and expands a new view angle for developing medicines for efficiently treating lung adenocarcinoma, so that the method has good practical application value.

The application provides a nucleic acid molecule, a pro-angiogenic mesenchymal stromal cell and application thereof, relates to the biomedical technical field, and the nucleic acid molecule encodes HGF protein, or encodes VEGF165 protein and HGF protein; a first signal peptide is used as the signal peptide of the VEGF165 protein, and a second signal peptide is used as the signal peptide of the HGF protein. Through a gene modification strategy, MSC cells containing the nucleic acid molecule can stably and efficiently express VEGF165 and / or HGF, and the expression amount is significantly higher than that of MSC without the nucleic acid molecule. The cells have the ability to promote the migration of endothelial cells; meanwhile, the cells can also significantly promote the proliferation and tube formation of HUVEC cells, and further confirm the strong pro-angiogenic effect. The technical problem that nucleic acid molecules expressing VEGF165 or / HGF cannot be stably and efficiently expressed in the prior art is solved.

The invention discloses cell-free fat extract loaded GelMA hydrogel and skin flap survival application, and particularly relates to the technical field of biomedical engineering. The hydrogel is prepared from GelMA, Ceffe, lithium phenyl (2, 4, 6-trimethylbenzoyl) phosphonate and a phosphate buffer salt solution. Wherein the Ceffe is rich in a plurality of angiogenesis promoting factors and is obtained through physical emulsification and centrifugal extraction; gelMA is prepared by modifying pig A-type gelatin through methacrylic anhydride, and has temperature-sensitive and photo-crosslinking characteristics. The injectable hydrogel with a porous network structure is formed by mixing Ceffe and a GelMA solution and curing through ultraviolet irradiation. The compound system realizes Ceffe biphasic slow release, remarkably promotes proliferation, migration and tube formation of vascular endothelial cells in vivo and in vitro, improves the survival rate of random skin flaps of mice, and effectively relieves oxidative stress injury caused by ischemia reperfusion by up-regulating HO-1 and down-regulating INOS.

1. Name of the designed product: cell tube formation plate (15 holes). 2. Use of the designed product: for culturing microorganisms, cells, etc. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view. 5. Other circumstances or explanations: the designed product is made of transparent material.

The invention discloses a preparation method and application of VEGF (vascular endothelial growth factor) engineered endothelial extracellular vesicles. The invention provides a specific preparation method, VEGF engineered endothelial extracellular vesicles (vEVs) and pharmaceutical application of the VEGF engineered endothelial extracellular vesicles. Compared with untreated common endothelial extracellular vesicles (EVs), the yield of the vEVs prepared by the invention is higher, and the vEVs are rich in higher-level angiogenesis promoting factors such as VEGF (vascular endothelial growth factor) and the like, show remarkably enhanced endothelial cell migration and tube formation promoting capability and accelerate endothelial cell uptake efficiency. The invention can be used for preparing medicines for promoting tissue repair and revascularization, and particularly has wide application prospects in the fields of diabetes wound healing, ischemic disease treatment and the like.

The utility model discloses an adjustable tracheotomy tube blocking device which comprises a tracheotomy sleeve connecting tube, an inner core tube is arranged on the tracheotomy sleeve connecting tube, a screw cap is arranged on the inner core tube, and manual adjusting blocking pieces used for adjusting air inflow are arranged on the screw cap and the inner core tube. According to the utility model, the tracheal ventilation volume can be adjusted according to the requirements of patients, so that the safety problems of suffocation, respiratory distress and the like caused by the fact that many tracheotomy patients cannot tolerate totally-closed tube blockage are solved, the gradual tube blockage training rehabilitation of the patients is better facilitated, and the tube drawing success rate of the tracheotomy patients is improved.

This application provides a polypeptide whose amino acid sequence includes the amino acid sequence shown in SEQ ID NO.1. The amino acid sequence of SEQ ID NO.1 is GPPVSE. This application also provides the application of the above-mentioned polypeptide in medical aesthetics and tissue repair products that promote cell proliferation and migration and endothelial tube formation. This application also provides a tissue repair product comprising the above-mentioned polypeptide. This application conducts research and development on polypeptide components in placental polypeptide extracts, and identifies and screens a monomeric polypeptide component that promotes tissue repair from placental polypeptide extracts.

This invention discloses the application of GLPG0187 in combination with propranolol in the preparation of drugs for the treatment or inhibition of hemangiomas. GLPG0187 is an integrin β1 inhibitor, and propranolol is a β-receptor blocker. This invention was validated through CCK8 assays, scratch assays, and tube formation assays. The results showed that, compared with propranolol monotherapy, GLPG0187 (4 nM) combined with propranolol (20-30 μM) could further inhibit the proliferation, migration, and tube formation ability of human hemangioma endothelial cells, demonstrating superior efficacy compared to propranolol monotherapy. This invention addresses the issue that approximately 2.1% of patients treated with propranolol monotherapy for infantile hemangiomas experience side effects such as sleep disturbances, bronchospasm, and hypoglycemia, providing a new combination therapy regimen and offering a new drug option for reducing the clinical dosage of propranolol and minimizing the risk of side effects. This invention identifies a new target for the treatment of hemangiomas, providing new possibilities for hemangioma treatment.

The utility model relates to the technical field of cell culture, in particular to a special culture plate for a cell tubulation experiment, which comprises a cell tubulation culture plate, a plurality of groups of positioning rotating holes are uniformly formed in the cell tubulation culture plate, and a group of controllable dynamic culture trays are connected in each positioning rotating hole in an inserted manner. A plurality of groups of cell culture tubes for tube culture of cells are uniformly mounted in the top of the controllable dynamic culture tray, a rotary supporting bottom column is mounted in the middle of the bottom of the controllable dynamic culture tray, the bottom end of the rotary supporting bottom column and the inner bottom wall of the positioning rotary hole are positioned in a rotary magnetic attraction manner, and a circle of driven straight teeth are mounted in the middle of the rotary supporting bottom column; a group of driving straight teeth are rotationally arranged in the gear space, one side of each driving straight tooth is in meshed connection with a driven straight tooth inserted into the positioning rotating hole, and the bottom of each driving straight tooth is connected with a micro servo motor arranged in a groove in the bottom wall in the gear space. The culture plate realizes a use mode of integrated design of dynamic culture and static culture.